Solacium Pharma S.R.L., a prominent player in the pharmaceutical industry, is headquartered in Romania (RO) and operates extensively across various regions. Founded in 2015, the company has quickly established itself as a leader in the development and distribution of innovative healthcare solutions. Specialising in high-quality generic medications and advanced therapeutic products, Solacium Pharma is committed to enhancing patient care through its unique formulations and rigorous quality standards. The company’s dedication to research and development has led to significant milestones, positioning it as a trusted name in the market. With a focus on affordability and accessibility, Solacium Pharma continues to make strides in the pharmaceutical landscape, ensuring that essential medications are available to those in need.
Solacium Pharma S.R.L., headquartered in Romania, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Zentiva Group, a.s., which may influence its climate commitments and performance metrics. While Solacium Pharma has not established its own reduction targets or climate pledges, it inherits sustainability initiatives from its parent company, Zentiva Group, a.s. This includes potential commitments to the Science Based Targets initiative (SBTi) and other climate-related frameworks, although specific details on these initiatives are not disclosed. As a part of the pharmaceutical industry, Solacium Pharma is positioned within a sector increasingly focused on reducing carbon footprints and enhancing sustainability practices. The absence of direct emissions data highlights the need for the company to develop and communicate its own climate strategies and performance metrics in alignment with industry standards.
Access structured emission data, company specific emission factors, and source documents.
The vast majority of Solacium Pharma S.R.L.'s reported carbon footprint comes from their downstream categories, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 1818% of total reported Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Solacium Pharma S.R.L. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Book a demo for your project.